Alpha-Lipoic Acid: The Antioxidant for Nerve Health

5 min read ·
Bottom Line

Alpha-lipoic acid (ALA) is a sulfur-containing antioxidant whose strongest evidence is for diabetic peripheral neuropathy — the burning, tingling and numbness of nerve damage in diabetes. The landmark trials are clear: a pooled analysis found 600 mg/day produces a meaningful reduction in nerve pain, and in Germany prescription ALA has been a standard neuropathy treatment for decades. The 600 mg dose hits the best balance of benefit and tolerability, and oral works for most people even though the most definitive data used an intravenous form over three weeks. The pricier “R-ALA” form is better absorbed in theory, but the trials that built the evidence used ordinary racemic ALA, so the standard form at 600 mg/day is what is actually proven.

Alpha-lipoic acid (ALA) is a small sulfur-containing molecule. It works as a cofactor in the energy-making reactions of mitochondria and as an antioxidant that operates in both the watery and fatty parts of the cell — an unusual feature that lets it neutralize free radicals almost anywhere in the body. The body makes a little on its own, and supplemental doses are typically 300–600 mg/day.

Diabetic Neuropathy: The Core Evidence

The ALADIN (Alpha-Lipoic Acid in Diabetic Neuropathy) program built the clinical foundation. ALADIN I (Ziegler et al., Diabetologia, 1995) randomized 328 adults with type 2 diabetes and symptomatic neuropathy. Intravenous ALA at 600 mg/day for 3 weeks reduced neuropathic symptoms (pain, burning, tingling, numbness) versus placebo. The SYDNEY 2 trial (Ziegler et al., Diabetes Care, 2006; PMID 17065669) tested oral ALA at 600, 1,200, or 1,800 mg/day for 5 weeks in 181 patients and showed a clinically meaningful drop in symptoms at all three doses, with the best risk-to-benefit ratio at 600 mg/day. A 2012 meta-analysis (Mijnhout et al., International Journal of Endocrinology; PMID 22331979) pooled the available trials and concluded that 600 mg/day IV ALA over 3 weeks produces a significant and clinically relevant reduction in neuropathic pain (Grade A recommendation); the evidence for oral ALA over 3–5 weeks is supportive but less definitive.

R-ALA vs. Racemic ALA

Alpha-lipoic acid comes as two mirror-image forms: R-lipoic acid (the natural, biologically active form) and S-lipoic acid. Most supplements contain a 50/50 racemic mix. R-ALA is the form used in mitochondrial reactions and is roughly 40–50% more bioavailable than racemic ALA in pharmacokinetic studies. Stabilized R-ALA (often as sodium R-lipoate) is sold but costs more. Note that the trials that built the neuropathy evidence used racemic ALA at 600 mg/day. R-ALA may have theoretical advantages, but racemic ALA at trial-validated doses is well supported.

Blood Sugar Effects

ALA boosts glucose uptake by activating AMPK and helping move GLUT4 transporters to the cell surface. Multiple trials have shown small but statistically significant drops in fasting blood glucose and HbA1c at 300–600 mg/day in type 2 diabetes. This is useful, but it also means ALA can interact with insulin and oral diabetes medications and could trigger hypoglycemia. People on metformin, sulfonylureas, or insulin should start at the low end of the dose range and check their blood sugar more often.

Dosing and Practical Tips

The evidence-based oral dose for neuropathy is 600 mg/day on an empty stomach (food cuts ALA absorption by about 30%). Doses above 600 mg/day didn’t add benefit in SYDNEY 2 and increased GI side effects (nausea, stomach upset). ALA can also recycle other antioxidants (vitamins C and E, glutathione, CoQ10) and binds certain metals, giving it a broad biochemical footprint. For people without diabetes, ALA at 300–600 mg/day is sometimes used for general antioxidant support, but the evidence is much weaker outside the neuropathy setting.

Sources

  1. Ziegler D, et al. “Oral treatment with α-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial.” Diabetes Care, 2006. PMID 17065669.
  2. Ziegler D, et al. “Treatment of symptomatic diabetic peripheral neuropathy with the antioxidant alpha-lipoic acid: the ALADIN study.” Diabetologia, 1995.
  3. Mijnhout GS, et al. “Alpha lipoic acid for symptomatic peripheral neuropathy in patients with diabetes: a meta-analysis of randomized controlled trials.” International Journal of Endocrinology, 2012. PMID 22331979.
  4. Han T, et al. “A systematic review and meta-analysis of α-lipoic acid in the treatment of diabetic peripheral neuropathy.” Endocrine, 2012.

Related supplements